Commercializing The INTERCEPT System
Commercializing the INTERCEPT System for Platelets and Plasma
Commercializing the INTERCEPT platelet and plasma systems remains our top priority. Cerus holds worldwide commercialization rights for INTERCEPT. Under the restructured agreement with Baxter announced in February 2005 and February 2006, we are directly responsible for the worldwide development and commercialization of the INTERCEPT Blood System. In March 2007, Baxter spun-off the division with which Cerus had worked to a private equity group, which renamed the division Fenwal, Inc. Fenwal is responsible for certain manufacturing activities through 2013 for the INTERCEPT platelet and plasma systems. We have established a subsidiary based in The Netherlands to market and sell the INTERCEPT platelet and plasma systems in Europe, Russia, the Middle East and in selected countries in other regions around the world. The platelet and plasma systems are not yet approved for sale in the United States.
Distribution Partners
We have entered into geographical distribution agreements for the distribution and sale of INTERCEPT in a number of countries. These distribution agreements are consistent with our overall strategy to support the rollout of the INTERCEPT system without investing in customer service and sales groups in territories where it would be too costly to build our own presence.
|
